Intellicheck, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Intellicheck, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.33M | Mar 21, 2019 |
| FY2018 | Sep 30, 2018 | $1.04M | Mar 21, 2019 |
| FY2018 | Jun 30, 2018 | $1.00M | Mar 21, 2019 |
| FY2018 | Mar 31, 2018 | $1.06M | Mar 21, 2019 |
| FY2018 | Dec 31, 2017 | $967.0K | Mar 21, 2019 |
| FY2018 | Sep 30, 2017 | $967.0K | Mar 21, 2019 |
| FY2018 | Jun 30, 2017 | $951.0K | Mar 21, 2019 |
| FY2018 | Mar 31, 2017 | $713.0K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $734.0K | Mar 23, 2018 |
| FY2017 | Sep 30, 2016 | $1.21M | Mar 23, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.67M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $20.00M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $18.91M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.97M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $16.39M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $10.74M | Jun 9, 2022 |
| FY2019 | Dec 31, 2019 | $2.90M | Mar 19, 2020 |
| FY2019 | Sep 30, 2019 | $1.93M | Mar 19, 2020 |
| FY2019 | Jun 30, 2019 | $1.56M | Mar 19, 2020 |
| FY2019 | Mar 31, 2019 | $1.28M | Mar 19, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $6.61M | Mar 30, 2015 |
| FY2014 | Dec 31, 2013 | $7.30M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $8.80M | Mar 25, 2014 |
| FY2012 | Dec 31, 2011 | $12.48M | Mar 27, 2013 |
| FY2011 | Dec 31, 2010 | $12.29M | Mar 8, 2012 |
| FY2011 | Dec 31, 2009 | $12.41M | Mar 8, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.50M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $18.17M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $17.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.69M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.88M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $9.31M | Jun 9, 2022 |
| FY2019 | Dec 31, 2019 | $2.57M | Mar 19, 2020 |
| FY2019 | Sep 30, 2019 | $1.67M | Mar 19, 2020 |
| FY2019 | Jun 30, 2019 | $1.34M | Mar 19, 2020 |
| FY2019 | Mar 31, 2019 | $1.09M | Mar 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.27M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($918.0K) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($1.98M) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | ($724.0K) | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | ($853.0K) | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | ($1.39M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($4.16M) | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | ($798.0K) | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | ($1.17M) | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | ($1.54M) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($1.17M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($2.28M) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | ($895.0K) | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | ($849.0K) | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | ($1.38M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($4.03M) | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | ($798.0K) | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | ($1.17M) | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | ($1.54M) | Apr 1, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.31M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.86M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.68M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.48M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $3.68M | Jun 9, 2022 |
| FY2020 | Dec 31, 2019 | $3.66M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.90M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.92M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $2.41M | Mar 23, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.10M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $15.48M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $15.13M | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | $3.68M | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | $3.94M | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | $4.00M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $12.71M | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | $2.99M | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | $3.20M | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | $3.02M | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.54M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($2.69M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($647.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.48M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.12M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($19.0K) | Jun 9, 2022 |
| FY2020 | Dec 31, 2019 | ($1.84M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($4.22M) | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | ($3.75M) | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | ($4.24M) | Mar 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.0K | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $57.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $93.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $192.0K | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | $44.9K | Mar 29, 2021 |
| FY2020 | Dec 31, 2019 | $20.1K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $141.5K | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $37.6K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $64.1K | Mar 23, 2018 |
| FY2016 | Dec 31, 2015 | $126.6K | Mar 30, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.48M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $20.93M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $23.81M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $22.45M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $25.71M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $24.34M | Jun 9, 2022 |
| FY2020 | Dec 31, 2019 | $14.00M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $14.46M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $17.88M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $14.53M | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.78M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.19M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $6.53M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.79M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.13M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.13M | Jun 9, 2022 |
| FY2020 | Dec 31, 2019 | $2.25M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.54M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $1.87M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.60M | Mar 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.70M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $17.75M | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $17.28M | Mar 19, 2026 |
| FY2023 | Sep 30, 2023 | $16.01M | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | $16.35M | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | $16.92M | Apr 1, 2024 |
| FY2024 | Dec 31, 2022 | $17.67M | Mar 31, 2025 |
| FY2023 | Sep 30, 2022 | $17.58M | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | $17.68M | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | $18.33M | Apr 1, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.10M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $8.10M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $8.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.10M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.10M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $8.10M | Jun 9, 2022 |
| FY2020 | Dec 31, 2019 | $8.10M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $8.10M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | $8.10M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $8.10M | Mar 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($133.21M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($134.48M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($133.57M) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | ($134.55M) | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | ($133.83M) | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | ($132.97M) | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | ($131.59M) | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | ($130.94M) | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | ($130.14M) | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | ($128.97M) | Apr 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.65M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.67M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.20M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $13.65M | Mar 28, 2023 |
| FY2017 | Dec 31, 2017 | $8.01M | Mar 23, 2018 |
| FY2016 | Dec 31, 2016 | $3.09M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $5.95M | Mar 30, 2017 |
| FY2016 | Dec 31, 2014 | $2.97M | Mar 30, 2017 |
| FY2015 | Dec 31, 2013 | $224.4K | Mar 25, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Apr 1, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Apr 1, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.23M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | 19.78M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | 19.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 18.96M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 18.66M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 18.41M | Jun 9, 2022 |
| FY2020 | Dec 31, 2019 | 16.04M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 15.64M | Mar 19, 2020 |
| FY2018 | Dec 31, 2017 | 15.01M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 10.72M | Mar 23, 2018 |